ArticleNature reviews. Clinical oncology2020
Improved MHC II epitope prediction - a step towards personalized medicine.
Article in Nature reviews. Clinical oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- DYRK1B Inhibition by AZ191 Sensitizes High-Grade Serous Ovarian Cancer to Niraparib Through Promoting Apoptosis and Ferroptosis.Biomedicines · 2026Article
- EpiMII: Structure-Aware Graph Neural Networks for MHC-II Epitope Generation.Research (Washington, D.C.) · 2026Article
- EpiMII: Integrating Structure and Graph Neural Networks for MHC-II Epitope and Neoantigen Design.bioRxiv : the preprint server for biology · 2025Article
- Large-scale transcript variants dictate neoepitopes for cancer immunotherapy.Science advances · 2025Article
- Innovative Immunoinformatics Tools for Enhancing MHC (Major Histocompatibility Complex) Class I Epitope Prediction in Immunoproteomics.Protein and peptide letters · 2025Review
- TCR-T cell therapy: current development approaches, preclinical evaluation, and perspectives on regulatory challenges.Journal of translational medicine · 2024Review
- NitraTh epitope-based neoantigen vaccines for effective tumor immunotherapy.Cancer immunology, immunotherapy : CII · 2024Article
- MHCII-peptide presentation: an assessment of the state-of-the-art prediction methods.Frontiers in immunology · 2024Review
- Development of therapeutic vaccines for the treatment of diseases.Molecular biomedicine · 2022Review
- Neoantigen personalized vaccine plus anti-PD-1 antibody in cancer patients.Annals of translational medicine · 2022Article
- Identification of Immunogenic MHC Class II Human HER3 Peptides that Mediate Anti-HER3 CD4Cancer immunology research · 2022Article
- Computational mining of MHC class II epitopes for the development of universal immunogenic proteins.PloS one · 2022Article
- A Highly Effective System for Predicting MHC-II Epitopes With Immunogenicity.Frontiers in oncology · 2022Article
- Artificial Intelligence-Based Data-Driven Strategy to Accelerate Research, Development, and Clinical Trials of COVID Vaccine.BioMed research international · 2022Review
- Role of the major histocompatibility complex class II protein presentation pathway in bone immunity imbalance in postmenopausal osteoporosis.Frontiers in endocrinology · 2022Review
- Artificial intelligence applied in neoantigen identification facilitates personalized cancer immunotherapy.Frontiers in oncology · 2022Review
- Artificial Intelligence in Surveillance, Diagnosis, Drug Discovery and Vaccine Development against COVID-19.Pathogens (Basel, Switzerland) · 2021Review
- The Macroautophagy Machinery in MHC Restricted Antigen Presentation.Frontiers in immunology · 2021Review
- Article
- Screening Cancer Immunotherapy: When Engineering Approaches Meet Artificial Intelligence.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2020Review
Corrections and comments
- Comment on
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.